Andere Kunden interessierten sich auch für
![New Technologies in Radiation Oncology]( "New Technologies in Radiation Oncology")
New Technologies in Radiation Oncology163,99 €![New Technologies in Radiation Oncology]( "New Technologies in Radiation Oncology")
New Technologies in Radiation Oncology183,99 €![Advances in Radiation Therapy]( "Advances in Radiation Therapy")
Advances in Radiation Therapy220,99 €![Californium-252 Isotope for 21st Century Radiotherapy]( "Californium-252 Isotope for 21st Century Radiotherapy")
Californium-252 Isotope for 21st Century Radiotherapy37,99 €![Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy]( "Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy")
Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy146,99 €![Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy]( "Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy")
Clinical Target Volumes in Conformal and Intensity Modulated Radiation Therapy95,99 €![Radiation Oncology]( "Radiation Oncology")
Radiation Oncology88,99 €
This book provides an up-to-date comprehensive overview of the exciting new developments shaping the current and future practice of radiation oncology. Advances in treatment planning and delivery, in biological targeted therapies combined with radiation and in functional and molecular imaging are all covered in a single volume. All of these advances are discussed by leading experts in the field and with a critical evaluation of their clinical relevance throughout.
from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
From the reviews: "Major advances in radiation oncology ... are reviewed in this book. ... Resident, attending and practicing radiation oncologists are the intended audience. The authors are respected radiation oncology practitioners and researchers. ... This excellent account of the major recent advances in radiation oncology is well written and edited. ... It is useful for both practicing and in-training radiation oncologists." (Jyoti Mayadev, Doody's Review Service, December, 2008)